The influence of HIV Env glycosylation on the conformation of the third variable domain (V3) of Env was studied by both deglycosylation of mature Env and the use of Env produced by recombinant systems in which ␣-glucosidase activity was inhibited by either deoxynojirimycin (DNM) or mutation. Selective deglycosylation affected anti-V3 antibody binding. The immunoreactivity and sensitivity to thrombin cleavage of V3 presented on Env produced in baby hamster kidney cells were changed by DNM treatment. In contrast, Env expressed in ␣-glucosidase I-deficient Chinese hamster ovary cells or in their parental cells treated by DNM fully retained these V3 properties. These results are discussed in relation to the inconsistent data obtained on V3 property changes resulting from Env glycosylation changes.
The mature human immunodeficiency virus (HIV) type I envelope (Env) contains gp120 and gp41, the cleavage products of the gp160 precursor: gp120 mediates HIVbinding to CD4 ϩ cells (1) and interacts with chemokine receptors (2) as part of post CD4-binding events leading to gp41-mediated fusion between the virus and the host cell membrane which is followed by virus entry (1) .
The third variable domain of gp120 (V3) is the principal neutralizing determinant (3) . V3 is also largely responsible for HIV tropism to either macrophages or T-cell lines, partially through its selective interaction with chemokine receptors (2, 4, 5) . It is a 35-amino-acid (aa) disulfidebonded loop which usually has one glycosylation site at its N-terminus and a conserved motif at its crown (3) . Cleavage within this motif (GPGR1AFVT) by thrombinlike proteases may be involved in the Env conformation changes required for gp41 to induce membrane fusion (6) . There are many lines of evidence that V3 sensitivity to thrombin cleavage, post-CD4-binding events and HIV infectivity are connected: (i) V3 susceptibility to thrombin cleavage is correlated with tropism to T-cell lines or macrophages (7, 8) , (ii) antibodies preventing V3 cleavage by thrombin also inhibit membrane fusion (9), (iii) synthetic humate analogs derived from hydroquinone inhibit HIV infectivity by interference with the CD4-induced proteolytic cleavage of V3 (10), (iv)``thrombin is less active with primary gp120 proteins compared to the laboratory adapted MN strain'' (11), (v) CD4 binding may induce and stabilize a trans to cis isomerization of the highly conserved Pro313, which would be essential for thrombin cleavage and subsequent infection (12) .
Env is heavily glycosylated. In BHK-21 cells and in CHO cells, about 10 high mannose and hybrid structures and 15 complex glycans make up 50% of its molecular mass (13, 14) . They are involved in Env folding (13±15) during biosynthesis as inhibitors of ␣-glucosidasesÐ such as deoxynojirimicin (DNM) which leads to the production of glycoproteins carrying predominantly neutral glucosylated high mannose type glycans (16)Ðimpair HIV infectivity in lymphocyte cultures (17±24). DNM may act partially by changing Env conformation (25±27). After biosynthesis, glycans are involved in Env resistance to various proteases (28) , including thrombin (29) .
The effects of changes in Env glycosylation on the conformation characteristics of its V3 loop are not clear (13±15). For example, in some studies, the binding of anti-V3 antibodies is affected by DNM (25, 27) , whereas, in other studies, apparently discrepant results were obtained (26, 30, 31) . The lack of agreement in the published results has been attributed to differences in the assays used or to the glycosylation patterns of Env from various cell origins (discussed in 13±15). Because recent studies suggest that V3 is very important in the post-CD4-binding events (summarized in 32), we felt that it was necessary to investigate the effect of Env glycosylation on the conformation of V3 to clarify this issue. We studied the effect on V3 properties of abnormal Env Lai glycosylation resulting from specific deglycosylation or from Env expression in cell systems where glucosidase activity was inhibited either by DNM or by mutation. We used both anti-V3 antibody binding and V3 susceptibility to thrombin to assess V3 conformation, as previously described (6±9, 25±27, 29, 31, 33±36) .
The effect of glycosidase treatment of mature Env on V3 conformation was studied. Purified soluble gp160 produced in baby hamster kidney (BHK-21) cells via a recombinant Env expressing vaccinia virus vector (VV1163; Transge Á ne S. A., Strasbourg, France; on the authentic HIV-1 Lai env gene, the sequence corresponding to cleavage sites has been altered and the transmembrane domain has been removed, as described in (37)) was radiolabeled (25 Ci/g; 28). We used an assay which detects changes in V3 reactivity in relation to changes in Env glycosylation (25, 27) . Native Env and Env treated by endoglycosidase H (Boehringer Mannheim, Germany; in Ref. 29 , the extent to which specific glycosidase treatments affect Env glycosylation is characterized), which cleaves high mannose structures, reacted similarly with 110-A (purchased from Institut Pasteur, Paris, France, 0 to 2 g/well; epitope: IQRGP N-terminal to the thrombin cleavage site) and 110-H (Institut Pasteur; 0 to 2 g/well; epitope: GPGRAFVTI at the crown of the loop) monoclonal antibodies (mAb) adsorbed onto microtiter wells (Nunc, Roskild, Denmark) (Figs. 1A and 1B). Treatment of Env with neuraminidase (type X; Sigma, St. Louis, MO; 29) to cleave sialic acid residues or with N-glycanase (Boehringer; 29) to fully deglycosylate Env resulted in changes in V3 immunoreactivity. V3 accessibility was also tested by susceptibility to thrombin cleavage: the various Env species were incubated overnight at 37°C with thrombin (0 to 150 mU/100 l). They were then incubated in anti-V3 mAb coated wells (1 g/well). As previously reported (6), mAbs directed against the crown of V3 (110-H and 9305 (DuPont de Nemours, Dreieich, Germany; IQRGPGRAFVTIGR) encompassing the thrombin cleavage site did not recognize Env once it was cleaved by thrombin within V3, whereas the binding of thrombin-treated Env to 110-A or 41a9 (Institut Pasteur; directed against gp41 aa 605±609) mAbs was unchanged ( Fig. 2A) . Treatment by 30 mU of thrombin resulted in a 50% loss of Env binding to mAb 110-H regardless of glycosylation state. Binding to 110-A mAb was assessed to evaluate the potential reactivity of the various Env samples after treatment with the maximal dose of thrombin and it was unaffected (Fig. 2B) . Thus, deglycosylation of Env, after biosynthesis, slightly affected V3 immunoreactivity but did not affect V3 susceptibility to thrombin. DNM (4 mM) exerts a major effect on the glycosylation pattern of glycoproteins produced by various mammalian cell lines (16) , including Env expressed in BHK-21 cells and in CHO cells (25, 31) . BHK-21 cells were treated for 2 weeks (25) by DNM and then infected with VV1163. The effects of the abnormal glycosylation of Env induced by DNM during biosynthesis on the characteristics of V3 was studied. Equivalent amounts of Env (0 to 100 ng/well assessed by dot-blot quantitation as in (25) (Figs. 1C and 1D) . The susceptibility to thrombin (0 to 125 mU/100 l) of these two preparations adsorbed onto 41a9-coated wells was also assessed. Treatment of DNM Ϫ Env (50 ng/well) with about 30 mU of thrombin resulted in a 50% decrease in binding of 110-H, which is consistent with both the data presented in Fig. 2A and the results of SDS±PAGE analysis (29) . In contrast, 3 mU of thrombin was sufficient to achieve a similar cleavage of the V3 loop of DNM ϩ Env (Fig. 2C) . These results suggest that there are changes in the V3 conformation of Env produced by BHK-21 cells as a result of DNM-induced changes in glycosylation.
These results conflict with reports of the lack of effect of DNM on anti-V3 antibody binding to Env expressed in Chinese hamster ovary (CHO) cells (26, 31) . We thus investigated, using the assays described above, the conformation properties of the V3 loop of Env expressed by an original recombinant system, i.e., CHO cells in which ␣-glucosidase activity was inhibited either by DNM treatment or by ␣-glucosidase mutation. The recombinant vaccinia virus vector used to express Env in CHO cells was obtained as described in (30) by coinfection of CHO cells with VV9-1 (37; it contains the authentic HIV-1 Lai env) and with VV6-3 (30; it contains the cowpox virus CPV hr gene to allow replication in CHO cells). gp120 encoded by env expressed by this vector in CHO cells and gp160 produced via VV1163 in BHK-21 cells are equally expressed and follow identical glycosylation and folding pathways (31, 38) . Env was then expressed in Lec 23, an ␣-glucosidase I deficient CHO cell line (39), in the presence or absence of DNM to inhibit any residual ␣-glucosidase activity or from its parental cell line in the presence or absence of DNM as described in (25, 31) . Env synthesized in the presence of DNM or in Lec23 cells presents a glycosylation pattern consistent with the presence of large glucosylated high mannose structures (30, 31) . All Env species (0 to 100 ng/well) bound to wells coated with D7324 (Aalto, Dublin, Eire; 200 ng/well; a polyclonal Ab against the C-terminus of gp120 that recognizes Env irrespective of its glycosylation state (26 and data not shown)) and reacted similarly with 110-A or 110-H mAb (Figs. 1E  and 1F ). As expected, in the absence of DNM, the cleaved secreted form of gp120 produced in this experiment and the soluble gp160 species expressed via VV1163 as described above reacted similarly with the anti-V3 mAbs studied here ( Fig. 1 ; C compared with E and D/F). The V3 susceptibility to thrombin (0 to 125 mU/100 l) of these preparations (50 ng/well) was also assessed after adsorption onto D7324-coated wells (Fig. 2D) : treatment with 3 mU of thrombin resulted in a 50% decrease in binding to 110-H, irrespective of the cellular origin of Env. Binding to 110-A mAb was not affected by thrombin treatment, indicating that it did not reduce adsorption of Env to the solid phase. Thus, the V3 conformation of Env produced by CHO cells was not affected by ␣-glucosidase I deficiency or DNM treatment.
We confirm and expand here previous reports on the relationship between Env glycosylation and V3 conformation. Our results are consistent with previous works showing that desialylation of mature Env increases V3 immunoreactivity (26) , whereas its deglycosylation re- duces anti-V3 antibody binding (25, 33) . Changes in Env glycosylation during biosynthesis affect the properties of V3: the abnormal glycosylation of Env resulting from DNM treatment of insect or mammalian cells affects both anti-V3 antibody binding (25, 27) and sensitivity to thrombin (24), as observed here for BHK-21 derived Env. Surprisingly, two independent groups observed that Env expressed in CHO cells in which ␣-glucosidase activity is inhibited retains its ability to mediate membrane fusion (30, 31) , its V3 immunoreactivity (26, 30, 31) , and its sensitivity to thrombin (26) . These reports are consistent with our data using both Lec23 cell line and its parental CHO cell line. Thus, it is clear that cell origin is the main cause of the discrepancies in the previous results discussed elsewhere (13±15, 31). The influence of the cell origin on the properties of V3 can be infered also from the observation that 10 times more thrombin was required to cleave BHK-21 cell-derived soluble gp160 (our data presented here) and BHK-21 cell-associated gp120 (M.-J. Papandre Â ou and E. Fenouillet, unpublished data) than for CHO cell-derived Env (our data presented here).
Further investigation of the impact of DNM on V3 structure should be carried out as one of the many strategies for preventing HIV infectivity. Indeed, in light of the recent literature, the central involvement of V3 in the various post-CD4-binding events leading to cell infection by HIV is clear (2) and our results suggest that the abnormal conformation of V3 induced by DNM treatment may be responsible for its effect on both the ability of Env to mediate membrane fusion and HIV infectivity (13±15).
The lack of effect of DNM in the CHO cell lines suggests that some cell lines, e.g., Lec23 cells, can develop alternative biosynthetic pathways (40±42) to overcome ␣-glucosidase deficiency and to allow the normal processing of Env required for correct folding. Such alternative biosynthetic pathways might be the emergence of an ␣-endomannosidase activityÐwhich may cleave Glc3Man9GlcNAc2 into Glc3Man and Man8GlcNAc2 (41)Ðor of a partially DNM-resistant ␣-glucosidase. It is also possible that the overexpression of a chaperone may overcome the effects of DNM on folding in the endoplasmic reticulum (40) . Such pathways may also occur in vivo and may partially explain why N-butyl DNM was not effective in anti-HIV trials (43) .
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